Efficacy of second-line ICI combined with TKI among patients with metastatic renal cell carcinoma: a real-world study. Supplementary data

Supplementary Figure 1. Kaplan-Meier curves for patients with ccRCC or non-ccRCC features. A (PFS2) and B (OS) represented survival outcomes of patents with ccRCC feature; C (PFS2) and D (OS) represented the survival outcomes of patients with non-ccRCC feature. Supplementary Figure 2. Kaplan-Meier curves for patients with second-line ICI plus TKI treatment (n = 52) in different IMDC risk groups. A (PFS2) and B (OS) represented survival outcomes of patents in IMDC favorable-, intermediate-, and poor-risk groups; C (PFS2) and D (OS) represented the survival outcomes of patients in the intermediate-risk group; E (PFS2) and F (OS) represented the survival outcomes of patients with different number of risk factors; G (PFS2) and H (OS) represented the comparasion of survival outcomes of patients with 0-1 and ≥2 risk factors. Supplementary Table 1. Univariate analysis of PFS and OS in mRCC patients (n = 110). Supplementary Table 2. Correlations of genomic mutations with survival outcome in mRCC patients with ICI plus TKI treatment (n = 52) Supplementary Table 3. Univariate analysis of PFS2 and OS in mRCC patients with ICI plus TKI treatment (n = 52)